Levelling the SPC playing field

“The EU’s highest court, in a 2013 ruling, held it is possible for a product to be classified as a medical device in one EU member state and a medicine in another.”

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

13 July 2026 The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.

Americas

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

10 July 2026 Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.

Americas

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

More features

UPC upholds injunction in Invisalign maker’s software dispute with rival

EU court under pressure to define SPC limits in patent row

Court narrows Mylan’s Copaxone suit but key claims survive

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

EPO reports record patent filings, but pharma and biotech lag

HSF Kramer hires patent litigator as partner in Germany

Emotional Perception: What next for patent holders?

Levelling the SPC playing field

More on this story

Editor's picks

Editor's picks

More features